Neurodegenerative disease is a completely different application than anything previously discussed for Iclusig. As you pointed out the ability to penetrate the BB barrier is only one aspect of potential efficacy. So far the overwhelming majority of trials for efficacious drugs in these indications have been costly exercises in futility. I hope they are doing preclinical studies. Perhaps someone else is going to be doing studies using the drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.